126 related articles for article (PubMed ID: 33893504)
1. Oestrogen receptor alpha in papillary thyroid carcinoma: association with clinical features and BRAFV600E mutation.
Liu S; Jiao B; Li S; Zhao L; Zheng W; Wang K; Xu J; Tian Y; Liu C; Gui Z; Zhang L
Jpn J Clin Oncol; 2021 Jul; 51(7):1051-1058. PubMed ID: 33893504
[TBL] [Abstract][Full Text] [Related]
2. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
3. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
[TBL] [Abstract][Full Text] [Related]
4. The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas.
Li Y; Wang Y; Li L; Qiu X
Sci Rep; 2022 Jul; 12(1):12674. PubMed ID: 35879379
[TBL] [Abstract][Full Text] [Related]
5. A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer.
Takacsova E; Kralik R; Waczulikova I; Zavodna K; Kausitz J
Neoplasma; 2017; 64(1):156-164. PubMed ID: 27881018
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the association of BRAFV600E mutation and Ki-67 overexpression with clinical and pathological characteristics in papillary thyroid cancer.
Espenbetova M; Krykpayeva A; Zamanbekova Z; Zhumanbaeva Z; Azizov B; Mukanova A; Glushkova N
Radiat Environ Biophys; 2021 May; 60(2):233-241. PubMed ID: 33774706
[TBL] [Abstract][Full Text] [Related]
7. BRAFV600E Mutation Enhances Estrogen-Induced Metastatic Potential of Thyroid Cancer by Regulating the Expression of Estrogen Receptors.
Kim M; Kim SJ; Ha SY; Xu Z; Han Y; Jee HG; Cho SW; Park YJ; Lee KE
Endocrinol Metab (Seoul); 2022 Dec; 37(6):879-890. PubMed ID: 36604958
[TBL] [Abstract][Full Text] [Related]
8. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
9. Single BRAFV600E mutation is not associated with aggressive biological behavior in adolescent and pediatric papillary thyroid carcinoma.
Zhou B; Lu X; Hei H; Zhang S; Li Y; Fang J; Qin J; Ge H
Cancer Cytopathol; 2023 Nov; 131(11):716-723. PubMed ID: 37519275
[TBL] [Abstract][Full Text] [Related]
10. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
11. The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Population of Fukushima.
Iwadate M; Mitsutake N; Matsuse M; Fukushima T; Suzuki S; Matsumoto Y; Ookouchi C; Mizunuma H; Nakamura I; Nakano K; Sakamoto A; Hirokawa M; Ito M; Naganuma H; Hashimoto Y; Shimura H; Yamashita S; Suzuki S
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32827026
[TBL] [Abstract][Full Text] [Related]
12. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
Kombak FE; Özkan N; Uğurlu MÜ; Kaya H
Turk Patoloji Derg; 2019; 35(2):83-91. PubMed ID: 30632125
[TBL] [Abstract][Full Text] [Related]
13. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients.
Yi JW; Kim SJ; Kim JK; Seong CY; Yu HW; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2017 Nov; 24(12):3754-3762. PubMed ID: 28124274
[TBL] [Abstract][Full Text] [Related]
15. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
[TBL] [Abstract][Full Text] [Related]
16. Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma.
Yoon JH; Han K; Lee E; Lee J; Kim EK; Moon HJ; Park VY; Nam KH; Kwak JY
PLoS One; 2020; 15(2):e0228968. PubMed ID: 32053670
[TBL] [Abstract][Full Text] [Related]
17. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
[TBL] [Abstract][Full Text] [Related]
18. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of conventional ultrasound features and related factors with BRAFV600E gene mutation in papillary thyroid carcinoma].
Lv Y; He X; Yang F; Guo L; Qi M; Zhang J; Wang H
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 Oct; 35(10):925-929. PubMed ID: 34628817
[No Abstract] [Full Text] [Related]
20. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.
Chai YJ; Yi JW; Jee HG; Kim YA; Kim JH; Xing M; Lee KE
PLoS One; 2016; 11(7):e0159235. PubMed ID: 27410688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
